Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exploring the Role of Target Expression in Treatment Efficacy of Antibody-Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review.
Mathiot L, Baldini C, Letissier O, Hollebecque A, Bahleda R, Gazzah A, Smolenschi C, Sakkal M, Danlos FX, Henon C, Beshiri K, Goldschmidt V, Parisi C, Patrikidou A, Michot JM, Marabelle A, Postel-Vinay S, Bernard-Tessier A, Loriot Y, Ponce S, Champiat S, Ouali K. Mathiot L, et al. Among authors: goldschmidt v. Curr Oncol Rep. 2024 Oct;26(10):1236-1248. doi: 10.1007/s11912-024-01576-9. Epub 2024 Jul 27. Curr Oncol Rep. 2024. PMID: 39066847 Review.
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V, Goldschmidt V, Laparra A, Messayke S, Danlos FX, Romano-Martin P, Champiat S, Voisin AL, Baldini C, Massard C, Laghouati S, Marabelle A, Lambotte O, Michot JM. Ruste V, et al. Among authors: goldschmidt v. Eur J Cancer. 2021 Nov;158:217-224. doi: 10.1016/j.ejca.2021.08.048. Epub 2021 Oct 7. Eur J Cancer. 2021. PMID: 34627664
Immunosenescence, inflammaging, and cancer immunotherapy efficacy.
Rodriguez JE, Naigeon M, Goldschmidt V, Roulleaux Dugage M, Seknazi L, Danlos FX, Champiat S, Marabelle A, Michot JM, Massard C, Besse B, Ferrara R, Chaput N, Baldini C. Rodriguez JE, et al. Among authors: goldschmidt v. Expert Rev Anticancer Ther. 2022 Sep;22(9):915-926. doi: 10.1080/14737140.2022.2098718. Epub 2022 Jul 14. Expert Rev Anticancer Ther. 2022. PMID: 35815381 Review.
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study.
Michot JM, Quivoron C, Sarkozy C, Danu A, Lazarovici J, Saleh K, El-Dakdouki Y, Goldschmidt V, Bigenwald C, Dragani M, Bahleda R, Baldini C, Arfi-Rouche J, Martin-Romano P, Tselikas L, Gazzah A, Hollebecque A, Lacroix L, Ghez D, Vergé V, Marzac C, Cotteret S, Rahali W, Soria JC, Massard C, Bernard OA, Dartigues P, Camara-Clayette V, Ribrag V. Michot JM, et al. Among authors: goldschmidt v. Am J Hematol. 2023 Apr;98(4):645-657. doi: 10.1002/ajh.26835. Epub 2023 Jan 18. Am J Hematol. 2023. PMID: 36606708 Free article.
Antibody drug conjugates in older patients: State of the art.
Rached L, Geraud A, Frelaut M, Ap Thomas Z, Goldschmidt V, Beraud-Chaulet G, Nagera-Lazarovici C, Danlos FX, Henon C, Parisi C, Gazzah A, Bahleda R, Postel Vinay S, Smolenschi C, Hollebecque A, Michot JM, Ribrag V, Loriot Y, Champiat S, Ouali K, Massard C, Ponce Aix S, Bringuier M, Baldini C. Rached L, et al. Among authors: goldschmidt v. Crit Rev Oncol Hematol. 2024 Jan;193:104212. doi: 10.1016/j.critrevonc.2023.104212. Epub 2023 Nov 24. Crit Rev Oncol Hematol. 2024. PMID: 38007063 Review.
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review.
Géraud A, Hueso T, Laparra A, Bige N, Ouali K, Cauquil C, Stoclin A, Danlos FX, Hollebecque A, Ribrag V, Gazzah A, Goldschmidt V, Baldini C, Suzzoni S, Bahleda R, Besse B, Barlesi F, Lambotte O, Massard C, Marabelle A, Castilla-Llorente C, Champiat S, Michot JM. Géraud A, et al. Among authors: goldschmidt v. Eur J Cancer. 2024 Jul;205:114075. doi: 10.1016/j.ejca.2024.114075. Epub 2024 May 4. Eur J Cancer. 2024. PMID: 38733717 Review.
Impact of Clonal Hematopoiesis-Associated Mutations in Phase I Patients Treated for Solid Tumors: An Analysis of the STING Trial.
Rodriguez J, Baldini C, Bayle A, Pages A, Danlos FX, Vasseur D, Rouleau E, Lacroix L, Alonso de Castro B, Goldschmidt V, Seknazi L, Hollebecque A, Michot JM, Champiat S, Marabelle A, Ouali K, Marzac C, Ponce S, Micol JB, Chaput N, Massard C, Italiano A. Rodriguez J, et al. Among authors: goldschmidt v. JCO Precis Oncol. 2024 May;8:e2300631. doi: 10.1200/PO.23.00631. JCO Precis Oncol. 2024. PMID: 38815178 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 39112237
[Characterization of patients with Philadelphia negative myeloproliferative neoplasms and concomitant monoclonal gammopathies: Just coincidence?].
Corsini F, Peña C, Gajardo C, Goldschmidt V, Avendaño C, Contreras N, Bahamonde Á, Zambrano D, Graffigna P, Lizama V, Valladares X. Corsini F, et al. Among authors: goldschmidt v. Rev Med Chil. 2023 Nov;151(11):1501-1505. doi: 10.4067/s0034-98872023001101501. Rev Med Chil. 2023. PMID: 39270117 Free article. Spanish.
44 results